JAGSNPHARM

Jagsonpal’s recent quarterly results have been disappointing, with declines in sales and profits signalling short-term headwinds. Yet, the company’s longer-term performance tells a more positive story. Over the past five years, the stock has delivered a remarkable total return of 448.18%, vastly outperforming the Sensex’s 58.20% return over the same period. Extending the horizon to ten years, the stock’s return soars to 1501.73%, compared to the Sensex’s 208.56%. Year-to-date, the stock has gained 10.46%, significantly outperforming the Sensex’s negative 8.66% return. However, over the past year, the stock’s return was negative 3.59%, mirroring the benchmark’s decline. Despite this, the company’s profits have increased by 15.1% over the last year, indicating some resilience in earnings despite market pressures.